Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Need for Additional Financing

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 10, 2023 9:03pm

331 Views

Post# 35729755

RE:Need for Additional Financing

Even though the volume looks healthier now - it isn't.
It was never healthy in P1 or P2 during chronic either because of the make-up of characters.
We have too many flippers - that's what causes this movement.
Therefore - I don't care about price right now.

Dilution? Sure. But not yet.

Company is going to focus on P2 and during that time, you won't see any dilution - nor is it needed. IMO

Can they slow down spend - yup. Will they? Don't know.

I hope not .. not yet. Too many important things needed for 2024 and 2025.

Head down - focus on P2 - talk after P2 is done.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec